Cite
Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na+-dependent taurocholate cotransporting polypeptide activity.
MLA
Wang, Xue-jun, et al. “Irbesartan, an FDA Approved Drug for Hypertension and Diabetic Nephropathy, Is a Potent Inhibitor for Hepatitis B Virus Entry by Disturbing Na+-Dependent Taurocholate Cotransporting Polypeptide Activity.” Antiviral Research, vol. 120, Aug. 2015, pp. 140–46. EBSCOhost, https://doi.org/10.1016/j.antiviral.2015.06.007.
APA
Wang, X., Hu, W., Zhang, T., Mao, Y., Liu, N., & Wang, S. (2015). Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na+-dependent taurocholate cotransporting polypeptide activity. Antiviral Research, 120, 140–146. https://doi.org/10.1016/j.antiviral.2015.06.007
Chicago
Wang, Xue-jun, Wei Hu, Ting-yu Zhang, Ying-ying Mao, Nan-nan Liu, and Sheng-qi Wang. 2015. “Irbesartan, an FDA Approved Drug for Hypertension and Diabetic Nephropathy, Is a Potent Inhibitor for Hepatitis B Virus Entry by Disturbing Na+-Dependent Taurocholate Cotransporting Polypeptide Activity.” Antiviral Research 120 (August): 140–46. doi:10.1016/j.antiviral.2015.06.007.